Mass Spectrometry of Peptides

Overview

Mass spectrometry (MS) measures the mass-to-charge ratio of ionized molecules, producing high-resolution data on chemical composition, sequence, and abundance. For peptides, MS can confirm amino acid sequence, detect post-translational modifications, identify impurities, and quantify levels in biological samples. Modern liquid chromatography-mass spectrometry (LC-MS/MS) combines chromatographic separation with tandem mass spectrometry to provide both specificity and sensitivity.

The rise of peptide mass spectrometry paralleled advances in ionization methods. Electrospray ionization (ESI), developed by John Fenn (Nobel Prize in Chemistry, 2002), and matrix-assisted laser desorption/ionization (MALDI), developed by Koichi Tanaka (also 2002 Nobel laureate) and Michael Karas, made it possible to ionize large biomolecules including peptides without fragmentation. These methods transformed what had been a niche technique into a routine tool.

For peptide drugs, MS now serves in multiple roles: confirming identity during manufacturing, characterizing impurities and degradation products, measuring pharmacokinetics in clinical samples, and supporting biomarker discovery.

Key Concepts

• Ionization methods: ESI for solution samples, MALDI for spotted samples.
• Mass analyzers: Quadrupole, ion trap, time-of-flight (TOF), Orbitrap, Fourier transform.
• Tandem MS (MS/MS): Selection of a precursor ion, followed by fragmentation and analysis of fragments for sequence information.
• LC-MS: Front-end liquid chromatography separates peptides before MS.
• Selected reaction monitoring (SRM): Highly specific, quantitative mode used in clinical bioanalysis.
• De novo sequencing: Determining sequence without a reference database.

Background

Peptide MS began as a research technique for protein identification in proteomics. The sequencing of the human genome made it possible to match MS fragmentation data against predicted tryptic peptides, allowing identification of thousands of proteins from complex mixtures. This capability transformed molecular biology and drove development of increasingly sensitive and selective instruments.

In parallel, LC-MS/MS matured as a quantitative tool. Pharmaceutical companies adopted MS methods to replace some classic immunoassays, particularly for small peptides, drugs with complex metabolism, and cases where assay specificity was critical. Regulatory authorities now accept well-validated LC-MS/MS methods for bioanalytical support of clinical trials.

Common Applications

Peptide MS applications include:

• Identity confirmation: Drug substance lot release.
• Impurity profiling: Detection of synthesis-related peptide impurities.
• Stability-indicating methods: Detection of degradation products.
• Pharmacokinetic assays: Measurement of drug in plasma or tissue.
• Biomarker quantification: Targeted measurement of specific peptides for research or diagnostics.
• Post-translational modification characterization: Glycosylation, phosphorylation, acetylation, sulfation.

Modern Relevance

Mass spectrometry has become essential to peptide drug development and research. Regulatory filings for new peptide drugs typically include extensive MS characterization, and many bioanalytical assays are now MS-based. Modern Orbitrap and time-of-flight instruments provide the mass accuracy needed to distinguish closely related peptides, including synthesis impurities with single-amino-acid differences from the target.

Clinical mass spectrometry is a growing field. Steroid panels, newborn screening for inborn errors of metabolism, therapeutic drug monitoring for some biologics, and emerging clinical biomarker assays all rely on MS. As instruments become more affordable and software more automated, MS is gradually expanding into routine clinical laboratory use alongside established immunoassays. For closely related methods, see elisa-method and radioimmunoassay-method.

Related Compounds

• Insulin
• Semaglutide
• Liraglutide
• Teriparatide
• Octreotide